14. LIFE BELOW WATER

Dynamic Advisor Solutions LLC Lowers Holdings in Zoetis Inc. (NYSE:ZTS) – Defense World

Written by Amanda

Dynamic Advisor Solutions LLC decreased its stake in shares of Zoetis Inc. (NYSE:ZTSGet Rating) by 19.5% in the first quarter, Holdings Channel reports. The institutional investor owned 3,332 shares of the company’s stock after selling 805 shares during the quarter. Dynamic Advisor Solutions LLC’s holdings in Zoetis were worth $628,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of ZTS. Investment Research & Advisory Group Inc. bought a new stake in shares of Zoetis in the 4th quarter worth $26,000. Consolidated Planning Corp bought a new stake in shares of Zoetis in the 3rd quarter worth $28,000. Amplius Wealth Advisors LLC bought a new stake in shares of Zoetis in the 4th quarter worth $31,000. Aquire Wealth Advisors LLC bought a new stake in shares of Zoetis in the 4th quarter worth $32,000. Finally, City State Bank bought a new stake in shares of Zoetis in the 4th quarter worth $36,000. 90.73% of the stock is owned by institutional investors and hedge funds.

NYSE:ZTS opened at $174.61 on Friday. The stock has a 50-day simple moving average of $168.99 and a two-hundred day simple moving average of $192.21. Zoetis Inc. has a 52-week low of $154.18 and a 52-week high of $249.27. The company has a debt-to-equity ratio of 1.12, a quick ratio of 1.58 and a current ratio of 2.25. The firm has a market capitalization of $82.18 billion, a PE ratio of 40.05, a P/E/G ratio of 2.76 and a beta of 0.77.

Zoetis (NYSE:ZTSGet Rating) last released its quarterly earnings results on Thursday, May 5th. The company reported $1.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.22 by $0.10. Zoetis had a return on equity of 49.62% and a net margin of 26.27%. The business had revenue of $2 billion during the quarter, compared to analyst estimates of $1.98 billion. During the same quarter in the previous year, the company posted $1.26 earnings per share. Zoetis’s revenue for the quarter was up 6.9% on a year-over-year basis. Equities analysts forecast that Zoetis Inc. will post 5.05 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 1st. Shareholders of record on Thursday, July 21st will be issued a dividend of $0.325 per share. This represents a $1.30 annualized dividend and a yield of 0.74%. The ex-dividend date is Wednesday, July 20th. Zoetis’s dividend payout ratio is presently 29.82%.

A number of analysts have commented on ZTS shares. StockNews.com lowered Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 26th. Stifel Nicolaus cut their price objective on Zoetis from $275.00 to $225.00 in a report on Friday. The Goldman Sachs Group cut their price objective on Zoetis from $237.00 to $208.00 and set a “buy” rating for the company in a report on Thursday, May 19th. Finally, Citigroup cut their price objective on Zoetis from $232.00 to $208.00 and set a “neutral” rating for the company in a report on Wednesday, March 9th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $229.75.

In other news, Director Willie M. Reed sold 1,855 shares of the business’s stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $162.31, for a total value of $301,085.05. Following the transaction, the director now directly owns 6,782 shares in the company, valued at $1,100,786.42. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Roxanne Lagano sold 2,167 shares of the business’s stock in a transaction dated Tuesday, April 26th. The shares were sold at an average price of $178.96, for a total value of $387,806.32. Following the completion of the transaction, the executive vice president now owns 23,687 shares in the company, valued at $4,239,025.52. The disclosure for this sale can be found here. 0.12% of the stock is owned by insiders.

Zoetis Profile (Get Rating)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Recommended Stories

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSGet Rating).

Receive News & Ratings for Zoetis Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Zoetis and related companies with MarketBeat.com’s FREE daily email newsletter.

Source: defenseworld.net

About the author

Amanda

Hi there, I am Amanda and I work as an editor at impactinvesting.ai;  if you are interested in my services, please reach me at amanda.impactinvesting.ai